BioTuesdays Features Halia Therapeutics CEO

August 31, 2023

In a recent interview with BioTuesdays, Halia and Co-Founder David Bearss, P.HD., said that the company is “growing to become a leader in targeting the NLRP3 inflammasome through a unique mechanism of action.”

Closely-held Halia Therapeutics is developing a broad pipeline of novel therapies that are essential mediators of immune cell signaling with the potential to improve the lives of patients with inflammatory disorders and neurological diseases.

Read the Full Article Here »